Bosutinib
規格
380843-75-4CAS番号
700-455-1EC番号
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrileIUPAC名
C26H29Cl2N5O3化学式
530.4 g/mol分子量
Bosutinib; 380843-75-4; SKI-606; SKI 606; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; SK-606; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 5018V4AEZ0; CHEBI:39112; DTXSID10861568; 3-Quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-; bosutinibum; uglysycpd2; RefChem:58901; DTXCID40207910; L01XE14; 4-Anilinobenzo(g)quinoline-3-carbonitrile; 700-455-1; 943-866-3; 4-Anilino-3-quinolinecarbonitrile; Bosutinib (SKI-606); BOSULIF; SKI606; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (USAN); Bosutinib [USAN]; MFCD07367846; 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; BOSUTINIB ISOMER 1; CHEMBL288441; C26H29Cl2N5O3; SKI-606); 4-(2,4-dichloro-5-methoxy-anilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib [USAN:INN]; NCGC00241107-01; UNII-5018V4AEZ0; Bosutinib API; Bosutinib (Standard); Bosutinib,SKI-606; BOSUTINIB [INN]; BOSUTINIB [MI]; BOSUTINIB [VANDF]; PF-5208763; BOSUTINIB [MART.]; EC 700-455-1; BOSUTINIB [WHO-DD]; Bosutinib (SKI-606)?; MLS006011212; SCHEMBL158390; BDBM4552; GTPL5710; orb1225150; orb1310890; orb3141310; Bosutinib Isomer 1, Free Base; Bosutinib, >=98% (HPLC); SCHEMBL29350234; SCHEMBL29428159; EX-A391; UBPYILGKFZZVDX-UHFFFAOYSA-N; GLXC-90178; HMS2043A22; HMS3244A03; HMS3244A04; HMS3244B03; HMS3651C03; HMS3672K11; HMS3743E09; HMS5079M03; K00615a; EBC-11336; HB1323; HY-10158R; NSC765694; NSC799367; SK 606; AKOS015902521; AC-2413; CCG-208129; CS-0118; DB06616; FB19002; NSC-765694; NSC-799367; PB30881; SDCCGSBI-0646926.P001; NCGC00241107-03; NCGC00241107-05; NCGC00241107-06; AS-11064; HY-10158; SMR002530350; NS00002757; S1014; SW220197-1; D03252; AB01565836_03; EN300-7565041; F794031; Q894611; SR-01000941572; SR-01000941572-1; BRD-K99964838-001-01-0; BRD-K99964838-001-06-9; BRD-K99964838-001-11-9; BRD-K99964838-001-12-7; Z2216885221; 3-QUINOLINECARBONITRILE, 4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHYL-1-PIPERAZINYL)PROPOXY)-; 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile別名
Bosutinibを含む製品
BOSUTINIB ZENTIVA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 500 COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 500 mg, comprimé pelliculéBOSUTINIB ZENTIVA 400 mg, comprimé pelliculéBOSUTINIB ZENTIVA 100 mg, comprimé pelliculé
1/3ページ
Bosutinibを販売する企業
ML
MSN LaboratoriesIndiaRP
Reddy Pharma Iberia S.A.SpainLC
LEAP CHEM CO., LTD.1/2ページ